⚠  CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.
⚠  COVID-19: What Cancer Patients Should Know.
rutgers.edu  |  Search Rutgers  |  RBHS
Menu
Search

Rutgers Cancer Institute of New Jersey

 

195 Little Albany Street
New Brunswick, NJ 08903-2681
732-235-CINJ (2465)

Researcher Publications

Andrew M. Evens, FACP

Selected Publications

  1. Evens AM, Spies WG, Helenowski IB, Patton D, Spies S, Jovanovic BD, Miyata S, Hamilton E, Variakojis D, Chen J, Naumovski L, Rosen ST, Winter JN, Miller RA, Gordon LI. The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y] Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial. Clinical Cancer Research.2009; 15:6462-71. PMID: 19825958
  2. Evens AM,Sehn LH, Farinha P, Nelson BP, Raji A, Lu Y, Brakman A, Parimi V, Winter JN, Schumacker PT, Gascoyne RD, Gordon LI. Hypoxia-Inducible Factor-1 Alpha (HIF-1α) Expression Predicts Superior Survival in Diffuse Large B-Cell Lymphoma Patients Treated With R-CHOP. Journal of Clinical Oncology. 2010; 28:1017-24. PMID: 20048181
  3. Evens AM, David KA, Helenowski IB, Nelson B, Kaufman D, Kircher S, Gimelfarb, Hattersley E, Mauro L, Jovanovic B, Chadburn AM, Stiff P, Winter JN, Mehta J, Van Besien K, Gregory SA, Gordon LI, Shammo JM, Smith S, Smith SM. Multicenter Analysis of 80 Solid Organ Transplant Recipients with Posttransplantation Lymphoproliferative Disease (PTLD): Outcomes and Prognostic Factors in the Modern Era. Journal of Clinical Oncology.2010; 28:1038-46. PMID: 20085936
  4. Evens AM,Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap S, Dai MS, Chiu BCH, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. Rituximab­-associated hepatitis B virus (HBV) reactivation in lymphooproliferative diseases: meta-analysis and examination of FDA safety reports. Annals of Oncology. 22:1170-80. PMID: 21115603
  5. Bhalla S, Evens AM,Dai B, Prachand S, Gordon LI, Gartenhaus RB. The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma. 2011; 22:1183-95.
  6. Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B, Parsons B, Smith S, Larsen A, McKoy JM, Jovanovic B, Gregory S, Gordon LI, Smith SM. A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. 2012; 119:692-5. PMID: 2211703.
  7. Evens AM,Antillón M, Aschebrook-Kilfoy B, Chiu BC. Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis. Annals of Oncology 2012; 23:2128-37. PMID: 22241896
  8. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WW, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM,Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nature Genetics. 2012; 44:1321-5. PMID: 23143597
  9. Evens AM,Advani R, Press OW, Lossos IS, Vose JM, Hernandez-Ilizaliturri FJ, Robinson BK, Otis S, Dagan LN, Abdallah R, Kroll A, Yarber JL, Sandoval J, Parker LM, Gordon LI, Blum KA, Flowers C, Leonard JP, Habermann TM, Bartlett NL. Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis. Journal of Clinical Oncology, 2013; 31:4132-9. PMID: 24043736
  10. Evens AM,Rosen ST, Helenowski I, Kline J, Larsen A, Colvin J, Winter JN, Van Besien KM, Gordon LI, Smith SM. A Phase I/II Trial of Bortezomib Combined Concurrently with Gemcitabine for Relapsed or Refractory DLBCL and Peripheral T-cell Lymphomas. British Journal of Haematology. 2013; 163:55-61; PMID: 23927371
  11. Evens AM,Vanderplas A, LaCasce AS, Crosby AL, Nademanee AP, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg JW. Stem Cell Transplantation for Follicular Lymphoma Relapsed/Refractory After Prior Rituximab: A Comprehensive Analysis from the NCCN Lymphoma Outcomes Project. Cancer. 2013; 119:3662-71; PMID: 23921646
  12. Evens AM,Carson KR, Kolesar J, Nabhan C, Helenowski I, Islam N, Jovanovic B, Barr PM, Caimi PF, Gregory SA, Gordon LI.A Multicenter Phase 2 Study Incorporating High-Dose Rituximab and Liposomal Doxorubicin into the CODOX-M/IVAC Regimen for Untreated Burkitt Lymphoma. Annals of Oncology. 2013; 24:3076-81. PMID: 24146219
  13. Abramson JS, Feldman T, Kroll-Desrosiers AR, Muffly LS, Winer E, Flowers CR, Lansigan F, Nabhan C, Nastoupil LJ, Nath R, Goy A, Castillo JJ, Jagadeesh D, Woda B, Rosen ST, Smith SM, Evens AM. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Annals of Oncology. 2014; 25:2211-7. PMID: 25193992
  14. Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, Sprague J, Sirisawad M, Mani C, Yue J, Luan Y, Horton S, Graef T, Bartlett NL. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clinical Cancer Research.2015; 22:1059-66. PMID: 26482040.
  15. Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar A, Gartenhaus RB, Evens AM. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma. Cancer Research.2016; 76:3319-31. PMID: 26988986
  16. Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. 2016; 28:2199-2205. PMID: 27601462
  17. Beheshti A, Vanderburg C, McDonald JT, Ramkumar C, Kadungure T, Zhang H, Gartenhaus RB, Evens AM. A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma. PLoS One. 2017; 12(1):e0170521. PMID: 28107482
  18. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. 2017. 171:481-494; PMID: 2812286.
  19. Pilichowska M, Pittaluga, S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LS, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, Fenske TS, Friedberg JW, Vose JM, Blum KS, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM.Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Advances 2017; 1:2600-2609.
  20. Henderson TO, Parsons SK, Wroblewski K, Chen L, Hong F, Smith SM, McNeer J, Advani R, Gascoyne RD, Constine LS, Horning S, Bartlett NL, Shah B, Connors JM, Leonard J, Kahl BS, Kelly K, Schwartz CL, Li H, Friedberg JW, Friedman DL, Gordon LI, Evens AM.Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children’s Oncology Group (COG AHOD 0031) Comparative Analysis. 2018; 124:136-144. PMID: 28902390
  21. Kapadia B, Nanaji NM, Bhalla K, Bhandary B, Lapidus R, Beheshti A, Evens AM, Gartenhaus RB. Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL. Nature Communications. 2018; 9:829. PMID: 29483509
  22. McDonald JT, Kritharis A, Beheshti A, Pilichowska M, Burgess K, Ricks-Santi L, McNiel E, London CB, Ravi D, Evens AM. Comparative oncology DNA sequencing of canine T cell lymphoma via human hotspot panel. 2018; 9:22693-22702. PMID: 29854308
  23. Parsons SK, Kelly MJ, Cohen JT, Castellino SM, Henderson TO, Kelly KM, Keller FG, Henzer TJ, Kumar AJ, Johnson P, Meyer RM, Radford J, Raemaekers J, Hodgson DC, Evens AM. Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes. British Journal of Haematology. 2018; 182:212-221; PMID: 29707774
  24. Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD, Bociek GR, Klein AK, Winter JN, Gordon LI, Hamlin PA. Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma.Journal of Clinical Oncology. 2018; 30:3015-3022; PMID: 30179569.
  25. Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Alderuccio JP, Lossos IS, Mehra P, Portell CA, Goldman ML, Calzada O, Cohen JB, Hussain MJ, Ghosh N, Caimi P, Tiutan T, Martin P, Kodali A, Evens AM, Kahl BS. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. British Journal of Haematology. 2018; 184:524-535; PMID: 30575016.
  26. Chen BJ, Dashnamoorthy R, Galera P, Makarenko V, Chang H, Ghosh S, Evens AM. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma. 2019 Mar 12;10(21):2030-2040. PMID: 31007846
  27. Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, Smith SM, Friedberg JW. Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma. 2019; 134:1238-1246. PMID: 31331918
  28. Beheshti A, Stevenson K, Vanderburg C, Ravi D, McDonald JT, Christie AL, Shigemori K, Jester H, Weinstock DM, Evens AM. Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. Science Reports. 2019 Nov 20; 9(1):17161. PMID: 31748664
  29. Ravi D, Sarkar S, Purvey S, Passero F, Beheshti A, Chen Y, Mokhtar M, David K, Konry T, Evens AM. Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma. Leukemia. 2020; 34:1291-1304. PMID: 31772298
  30. Evens AM, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, Quon A, Ranheim EA, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JN, Cescon TP, Chang JE, Kahl B. A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab With Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clinical Cancer Research;2020; 26:4468-4477. PMID: 32532790
  31. Evens AM, Danilov AV, Jagadeesh D, Sperling AL, Kim SH, Vaca RA, Wei C, Rector D, Sundaram S, Reddy N, Lin Y, Farooq U, D'Angelo C, Bond D, Berg S, Churnetski MC, Godara A, Khan N, Choi YK, Sarraf Yazdy M, Rabinovich E, Varma G, Karmali R, Mian A, Savani M, Burkart M, Martin P, Ren A, Chauhan A, Diefenbach CS, Straker-Edwards A, Klein A, Blum K, Boughan K, Smith SE, Haverkos BM, Orellana-Noia VM, Kenkre V, Zayac AS, Ramdial J, Maliske S, Epperla N, Venugopal P, Feldman T, Smith SD, Stadnik A, David KA, Naik S, Lossos IS, Lunning M, Caimi PF, Kamdar M, Palmisiano N, Bachanova V, Portell CA, Phillips T, Olszewski AJ, Alderuccio JP. Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers. B 2020 Jul 14. Online ahead of print. PMID: 32663292
  32. Allen PB, Savas H, Evens AM, Advani R, Palmer B, Pro B, Karmali R, Mou E, Bearden J, Dillehay G, Bayer R, Eisner RM, Chmiel JS, O'Shea KL, Gordon LI, Winter JN. Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma. 2020 Sep 29; Online ahead of print. PMID: 32992341

Return to member profile